We’re dedicated to accelerating the adoption of precision medicine by delivering AI-driven pharmacogenomic insights that reduce adverse events, optimize therapy choices, and ultimately improve patient outcomes.

PGxAI was co-founded by experts in pharmacogenetics, AI/ML, and venture investing. Our leadership team includes Dr. Mike Zack (CEO & Co-Founder), Allan Gobbs (President & Co-Founder), and other industry veterans with decades of combined experience in healthcare innovation.

Our platform automates the creation of pharmacogenomic guidelines in near-real time using advanced AI models—dramatically cutting down the years of manual curation that many competitors face. We also integrate real-world data, ensuring our insights remain current and clinically relevant.

We provide tailored solutions for hospitals/health systems, diagnostic laboratories, CROs (clinical research organizations), payors (insurance companies), and individual patients—offering each stakeholder group the precision and workflow integration they need.

Our main operations and headquarters are in Palo Alto, California. However, we collaborate with partners and clients globally, adapting our solutions to various regulatory environments and healthcare practices.

We adhere to HIPAA and SOC 2 standards, ensuring robust encryption and strict access controls. Our partnership with InterSystems IRIS for Health supports fast, secure data handling on an enterprise scale, maintaining patient and client data confidentiality.

Absolutely. We frequently partner with academic institutions, biotech firms, and other research entities to refine our AI models, expand therapeutic coverage, and stay at the forefront of precision medicine innovation.

Yes. We’re always on the lookout for passionate professionals who want to transform healthcare through technology. Check out our Careers section for current openings and application details.